UFT/Leucovorin Plus Weekly Paclitaxel in the Treatment of Solid Tumors
ByCarsten Bokemeyer, MD,Jörg Thomas Hartmann, MD,Frank Mayer, MD,Lothar Kanz, MD,Joachim Von Pawel, MD,Gunther Derigs, MD,Michael Schröder, MD
Published: | Updated:
The palliation of symptoms and improvement of quality of life are important aspects of therapy in patients with incurable metastatic cancer. This article describes the preliminary results of a phase I study of uracil and tegafur, an orally available fluorouracil (5-FU) derivative combined with oral leucovorin plus weekly intravenous paclitaxel.